| Study shows patients treated with Smith+Nephew's CARTIHEAL™ AGILI-C™ Cartilage Repair Implant have an 87% lower relative risk of Total Knee Arthroplasty or Osteotomy at 4 years¹* |
The CARTIHEAL Implant will be featured at the Arthroscopy Association of North America Annual Meeting (AANA 2025) this week |
globenewswire.com |
2025-05-07 12:00:00 |
Czytaj oryginał (ang.) |
| Smith+Nephew to showcase its CORI™ Surgical System at surgical clinics across Germany, Austria and Switzerland |
“CORI on Tour” will highlight the latest advancements in robotics-assisted surgery for hip and knee joint replacement Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces a months-long roadshow across central Europe to promote its CORI Surgical System – an advanced robotics-assisted surgical platform for total knee and hip joint replacement procedures. The tour will commence in Berlin today and make dozens of stops at surgical facilities across Germany, Austria and Switzerland until returning to Berlin on 28 October for DKOU 2025 – the largest Orthopaedics congress in Europe. |
globenewswire.com |
2025-05-05 06:00:00 |
Czytaj oryginał (ang.) |
| Smith & Nephew plc (SNN) Q1 2025 Earnings Call Transcript |
Smith & Nephew plc (NYSE:SNN ) Q1 2025 Results Conference Call April 30, 2025 3:30 AM ET Company Participants Deepak Nath - Chief Executive Officer John Rogers - Chief Financial Officer Conference Call Participants Richard Felton - Goldman Sachs Julien Dormois - Jefferies Jack Reynolds-Clark - RBC Capital Markets Lisa Clive - Bernstein Hassan Al-Wakeel - Barclays Kane Slutzkin - Deutsche Bank David Adlington - JPMorgan Veronika Dubajova - Citi Dylan van Haaften - Stifel Robert Davies - Morgan Stanley Operator Ladies and gentlemen, welcome to the Smith & Nephew Q1 Trading Report. My name is Jenny, and I will be coordinating your call today. |
seekingalpha.com |
2025-05-02 21:42:04 |
Czytaj oryginał (ang.) |
| Smith & Nephew shares jump 7% on better-than-expected quarterly growth |
Smith & Nephew PLC (LSE:SN) rose as much as 7% in afternoon trading on Wednesday after the medical technology group reported stronger-than-expected revenue growth in the first quarter of 2025. The London-listed company posted underlying revenue growth of 3.1% in the three months to March, ahead market consensus of 1.9%. |
proactiveinvestors.co.uk |
2025-04-30 13:48:55 |
Czytaj oryginał (ang.) |
| Smith & Nephew jumps as hip and knee replacements in demand |
Smith & Nephew PLC (LSE:SN) shares rose over 5% to top the early FTSE 100 leaderboard on Wednesday after the knee and hip replacer maintained its full-year 2025 guidance after seeing growth of 3.1% in underlying revenue for the first quarter. The performance was supported by recent product launches and continued operational improvements across its business lines, with total reported revenue up 1.6% to $1.4 billion after a negative foreign exchange, ongoing headwinds from China and one fewer trading day compared to the prior year. |
proactiveinvestors.co.uk |
2025-04-30 07:17:24 |
Czytaj oryginał (ang.) |
| Is Smith & Nephew SNATS (SNN) a Great Value Stock Right Now? |
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. |
zacks.com |
2025-04-29 14:45:50 |
Czytaj oryginał (ang.) |
| New Strong Buy Stocks for April 29th |
MATX, SNN, ALEX, PCB and LTH have been added to the Zacks Rank #1 (Strong Buy) List on April 29, 2025. |
zacks.com |
2025-04-29 11:26:12 |
Czytaj oryginał (ang.) |
| Smith & Nephew: Underappreciated Recovery With Strategic Upside |
Smith & Nephew is undergoing a turnaround under CEO Deepak Nath, focusing on margin expansion and growth through surgical robotics and regenerative technologies. Despite trading at a discount to peers, the company shows visible margin improvement, offering a compelling value proposition for investors. The base case projects 35% upside by 2025 with a 20% trading margin, while the bull case suggests 50-60% upside with further margin gains. |
seekingalpha.com |
2025-04-20 02:09:29 |
Czytaj oryginał (ang.) |
| Trump tariffs: these two European healthcare stocks face the highest US revenue exposure |
Global financial markets are in turmoil this morning after the US President announced sweeping tariffs on several countries in a push to lower the nation's trade deficit. Trump's new tariffs are particularly expected to hurt European companies with significant revenue exposure to the United States. |
invezz.com |
2025-04-03 13:34:45 |
Czytaj oryginał (ang.) |
| Smith & Nephew falls after downgrade by leading investment bank |
Shares in Smith & Nephew PLC (LSE:SN) fell 2% after UBS downgraded stock in the med-tech firm to 'neutral' from 'buy' on valuation grounds. The price target remains at £12.50. |
proactiveinvestors.co.uk |
2025-03-12 09:41:43 |
Czytaj oryginał (ang.) |
| Smith+Nephew to showcase advanced Orthopaedic Reconstruction technologies for Robotics, Knees, Hips, and Shoulders at AAOS 2025 |
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it will feature the latest advancements in Orthopaedic Reconstruction at the American Academy of Orthopaedic Surgeons Annual Meeting in San Diego this week. Some of the highlighted technologies will include: |
globenewswire.com |
2025-03-11 13:00:00 |
Czytaj oryginał (ang.) |
| Smith+Nephew to highlight breakthrough Sports Medicine technologies for joint repair at AAOS 2025 |
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it will showcase the latest advancements in Sports Medicine for joint repair at the American Academy of Orthopaedic Surgeons Annual Meeting in San Diego this week. Some of the highlighted technologies will include: |
globenewswire.com |
2025-03-10 13:00:00 |
Czytaj oryginał (ang.) |
| New report confirms Smith+Nephew's OXINIUM™ Technology is the best performing bearing surface at 20 years for total hip arthroplasty |
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, is pleased to announce that the latest annual report from the Australian Orthopaedic Association National Joint Replacement Registry (AOANJRR) highlights the exceptional performance of Smith+Nephew's proprietary OXINIUM on highly cross-linked polyethylene. The data indicates that this combination has the highest survivorship rate (94.1%) among all bearing combinations over a 20-year period for total hip arthroplasty (THA).1 |
globenewswire.com |
2025-03-06 12:00:00 |
Czytaj oryginał (ang.) |
| Wound Care Market Size is Expected to Reach USD 32.75 Billion by 2033, Growing at a CAGR of 3.94%: Straits Research |
The global wound care market size was valued at USD 23.13 billion in 2024 and is projected to reach from USD 24.04 billion in 2025 to USD 32.75 billion by 2033, growing at a CAGR of 3.94% during the forecast period (2025-2033). The global wound care market size was valued at USD 23.13 billion in 2024 and is projected to reach from USD 24.04 billion in 2025 to USD 32.75 billion by 2033, growing at a CAGR of 3.94% during the forecast period (2025-2033). |
globenewswire.com |
2025-03-03 10:20:00 |
Czytaj oryginał (ang.) |
| We are having constructive engagement with activist shareholders, says Smith & Nephew CEO |
Deepak Nath, CEO of Smith & Nephew discusses spin offs, navigating the China market, and the medical tech firm's full-year earnings for 2024. |
youtube.com |
2025-02-25 13:00:44 |
Czytaj oryginał (ang.) |
| Smith & Nephew sees turnaround plan kicking in as profit grows |
Smith & Nephew PLC has said 2025 should show its transformation plan kicking in despite ongoing woes in China after improving trading over the last year. Revenue climbed 4.7% to US$5.8 billion in the year to December 31, the medical equipment maker said Tuesday, aiding an 8.2% increase in trading profit to US$1.1 billion. |
proactiveinvestors.co.uk |
2025-02-25 04:41:13 |
Czytaj oryginał (ang.) |
| UK's Smith+Nephew beats annual profit expectations |
Smith+Nephew beat analysts' expectations for annual sales and profit on Tuesday, as a recovery in its U.S. knee and hip implant business, along with cost cuts, helped the medical products maker offset the impact of weak demand from China. |
reuters.com |
2025-02-25 04:09:04 |
Czytaj oryginał (ang.) |
| Smith & Nephew has to impress in results after ringing warning bell |
Smith & Nephew PLC has left itself with the mounting task of having to give investors something to cheer about after ringing the warning bell last time out. Ahead of full-year figures on Tuesday, 25 February, AJ Bell analysts noted the medical equipment maker flagged it and chief executive Deepak Nath needed to reassure. |
proactiveinvestors.co.uk |
2025-02-21 09:18:11 |
Czytaj oryginał (ang.) |
| Smith+Nephew steps forward with innovative Sports Medicine foot & ankle repair solutions in Australia and New Zealand |
First in market to o ffe r A djustable T ensioning T echnology * for i nsertional A chilles r econstruction and l ateral a nkle i nstability r epair |
globenewswire.com |
2025-02-16 20:00:00 |
Czytaj oryginał (ang.) |
| Smith+Nephew and UFC to host first-of-its-kind medical education course for treatment of injuries in combat sport athletes |
Healthcare professionals are invited to register for the livestream option as a courtesy here |
globenewswire.com |
2025-02-03 12:00:00 |
Czytaj oryginał (ang.) |
| Smith & Nephew Getting No Credit For Self-Improvement Efforts |
Smith & Nephew's stock has underperformed, driven by ongoing market share losses in hip and knee markets and pricing pressures in China, raising concerns about its ongoing multiyear restructuring program. The upcoming fourth quarter results may not significantly help, given ongoing market share pressure in major joints, ongoing headwinds in China, and a lack of clear growth engines. Smith & Nephew needs to execute its self-improvement plan effectively to close the value gap and regain investor confidence in its turnaround strategy, particularly in the major joint business. |
seekingalpha.com |
2025-01-29 10:37:52 |
Czytaj oryginał (ang.) |
| Smith+Nephew's ALLEVYN™ LIFE Sacrum Foam Dressing and LEAF™ Patient Monitoring System receive ‘favorable' Evidence Bar™ ratings from ECRI for pressure injury prevention |
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces that ECRI – leaders in advancing evidence-based healthcare globally - have completed updated Clinical Evidence Assessments of ALLEVYN LIFE Sacrum Foam Dressings and the LEAF Patient Monitoring System. In their latest reports, ECRI upgraded its Evidence Bar ratings for both to favorable* after assessing the most recently published clinical evidence and key outcomes for pressure injury prevention. |
globenewswire.com |
2025-01-14 10:00:00 |
Czytaj oryginał (ang.) |
| Topical Scar Treatment Market to Grow from $1.71 Billion in 2024 to $5.91 Billion by 2035 - Dominated by Smith & Nephew, Molnlycke Health Care, Alliance Pharma, HRA Pharma, and Rejuvaskin |
Scar Treatment Market Booms with Rising Skin-Related Surgeries and Burn Cases Globally Scar Treatment Market Booms with Rising Skin-Related Surgeries and Burn Cases Globally |
globenewswire.com |
2025-01-14 06:22:00 |
Czytaj oryginał (ang.) |
| SNN Stock May Gain on CORIOGRAPH Platform's FDA Clearance for THA |
Smith & Nephew announces FDA clearance for its CORIOGRAPH platform for total hip arthroplasty. |
zacks.com |
2024-12-20 12:06:08 |
Czytaj oryginał (ang.) |
| Smith+Nephew introduces CORIOGRAPH™ Pre-Op Planning and Modeling Services for Total Hip Arthroplasty |
Latest expansion to the CORI◊ Surgical System portfolio provides a personalized solution for patients and surgeons Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces its CORIOGRAPH Pre-Op Planning and Modeling Services is now cleared for total hip arthroplasty (THA) by the United States Food and Drug Administration. Exclusively for users of the CORI Surgical System, this innovative planning software allows for use of either X-rays or CT scans for planning and modeling, enabling surgeons to make a patient-specific plan for the best possible outcome. |
globenewswire.com |
2024-12-19 12:00:00 |
Czytaj oryginał (ang.) |
| SNN Stock Might Rise Following FDA Nod for AETOS Stemless |
Smith & Nephew received FDA 510(k) clearance for a stemless anatomic total shoulder, AETOS Stemless. This represents a significant advancement in shoulder arthroplasty. |
zacks.com |
2024-12-17 10:45:37 |
Czytaj oryginał (ang.) |
| Smith+Nephew expands AETOS™ Shoulder System with new stemless option for anatomic shoulder arthroplasty |
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it has received 510(k) clearance from the United States Food & Drug Administration for a stemless anatomic total shoulder for the AETOS Shoulder System (AETOS Stemless). |
globenewswire.com |
2024-12-16 12:00:00 |
Czytaj oryginał (ang.) |
| Smith & Nephew has the potential to pop next year, says leading US investment bank |
JP Morgan has doubled down on its "overweight" recommendation for Smith & Nephew PLC (LSE:SN) with its analysts deeming the medical device company undervalued, trading near trough levels, with potential for significant re-rating. Despite challenges in the broader European medtech sector, S&N stands out as a value pick with promising recovery prospects. |
proactiveinvestors.co.uk |
2024-12-03 08:44:55 |
Czytaj oryginał (ang.) |
| Big investors call for break-up of Smith & Nephew, FT reports |
Three major investors are pushing medical device maker Smith & Nephew to consider a break-up of the business, the Financial Times reported on Thursday, citing shareholders. |
reuters.com |
2024-11-14 02:24:14 |
Czytaj oryginał (ang.) |
| Smith & Nephew: Ready To Reap Demographic, Turnaround Dividends |
Smith & Nephew's Q3 results led to a 13% share price drop due to reduced FY24 guidance, mainly from lower demand in China. Despite short-term challenges, long-term fundamentals remain strong, presenting a buying opportunity at current lower prices. The company's 12-point plan aims to boost growth and margins, focusing on orthopedics, productivity, and accelerating growth in advanced wound management and sports medicine. |
seekingalpha.com |
2024-11-10 15:02:00 |
Czytaj oryginał (ang.) |
| Smith & Nephew plc (SNN) Q3 2024 Earnings Conference Call Transcript |
Smith & Nephew plc (NYSE:SNN ) Q3 2024 Earnings Conference Call October 31, 2024 4:30 AM ET Company Participants Deepak Nath - CEO & Director John Rogers - CFO & Executive Director Conference Call Participants Jack Reynolds-Clark - RBC Capital Management David Adlington - J.P. Morgan Hassan Al-Wakeel - Barclays Robert Davies - Morgan Stanley Richard Felton - Goldman Sachs Graham Doyle - UBS Lisa Clive - Bernstein Julien Dormois - Jefferies Deepak Nath Good morning, and welcome to the Smith & Nephew third quarter trading update. |
seekingalpha.com |
2024-11-02 10:57:09 |
Czytaj oryginał (ang.) |
| Smith+Nephew slashes revenue outlook as China headwinds emerge |
British medical equipment manufacturer Smith & Nephew PLC (LSE:SN) slashed its full-year revenue outlook to account for a downturn in demand and pricing pressures in the Chinese market. The FTSE 100-listed group now expects full-year revenue growth of 4.5%, compared to 5-6% growth previously expected. |
proactiveinvestors.co.uk |
2024-10-31 06:16:02 |
Czytaj oryginał (ang.) |
| Smith & Nephew slashes annual revenue forecast on weak China |
British medical equipment maker Smith & Nephew cut its annual underlying revenue growth forecast on Thursday to 4.5% from the previous outlook range of 5% to 6%, primarily hurt by challenges in its surgical businesses in China. |
reuters.com |
2024-10-31 05:17:30 |
Czytaj oryginał (ang.) |
| RENASYS™ EDGE Negative Pressure Wound Therapy System wins Red Dot Award for Design |
Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology company, is proud to announce that its RENASYS EDGE Negative Pressure Wound Therapy (NPWT) System has won the Red Dot Award for Design Concept 2024 in the Medical Devices and Technology Category , recognizing its intuitive pairing of NPWT housed in a patient-friendly design. |
globenewswire.com |
2024-10-16 13:00:00 |
Czytaj oryginał (ang.) |
| SNN Stock May Gain Following the Co-Marketing Deal With JointVue |
Smith & Nephew and JointVue announce a co-marketing agreement for the latter's OrthoSonic 3D Surgery Planning Technology. |
zacks.com |
2024-10-15 17:36:17 |
Czytaj oryginał (ang.) |
| SNN Boosts Knee Revision Surgery With Its LEGION Hinged Knee System |
Smith & Nephew introduces the LEGION Hinged Knee System with OXINIUM Technology, elevating knee revision surgery through innovation. |
zacks.com |
2024-10-11 14:16:33 |
Czytaj oryginał (ang.) |
| Smith+Nephew partners with JointVue™ for Ultrasound preoperative planning in robotics-assisted surgery |
Patented technology further personalizes total knee arthroplasty for surgeons and patients Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it has signed a co-marketing agreement with JointVue for its patented OrthoSonic™ 3D Surgery Planning Technology – the only ultrasound device currently on the market to deliver 3D preoperative planning. JointVue's technology allows surgeons using Smith+Nephew's CORI◊ Surgical System for robotic-assisted knee arthroplasty to create a personalized surgical plan, which may provide opportunities to improve patient satisfaction and operating room efficiency. |
globenewswire.com |
2024-10-09 12:00:00 |
Czytaj oryginał (ang.) |
| SNN Stock Rises on the Completion of First Case With CATALYSTEM System |
Smith & Nephew announces the completion of the first case using the CATALYSTEM Primary Hip System. |
zacks.com |
2024-09-20 16:51:00 |
Czytaj oryginał (ang.) |
| This stock is 'boring' but has 'fantastic' risk-reward: Scharf |
Eric Lynch from Scharf Investments explains why he likes the non-tech and utilities sectors. |
youtube.com |
2024-09-18 16:40:08 |
Czytaj oryginał (ang.) |
| First cases using Smith+Nephew's new CATALYSTEM™ Primary Hip System completed; surgeons hail precision, efficiency and reproducibility |
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces promising surgeon feedback from the first completed cases utilizing its new CATALYSTEM Primary Hip System. Designed to address the evolving demands of primary hip surgery - including the increased adoption of anterior approach procedures – the CATALYSTEM Primary Hip System features a triple-taper stem design with uniform proximal loading.1 The reduced distal stem geometry and shorter lengths are ideal for anterior approach but suitable for all approaches.2 |
globenewswire.com |
2024-09-18 14:00:00 |
Czytaj oryginał (ang.) |
| SNN Stock Declines Despite the Launch of Its Patient-Matched Guides |
Smith & Nephew announces the launch of its TOTAL ANKLE Patient-Matched Guides to plan and perform total ankle replacement procedures. |
zacks.com |
2024-09-13 17:26:19 |
Czytaj oryginał (ang.) |
| Smith+Nephew brings pre-operative planning and accuracy to total ankle replacement with new TOTAL ANKLE Patient-Matched Guides |
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces the launch of its TOTAL ANKLE Patient-Matched Guides, giving surgeons a predictable and efficient option to help plan and perform total ankle replacement (TAR) procedures. Engineered using 3D Systems' VSP® surgical planning workflows, all-in-one TOTAL ANKLE Patient-Matched Guides are designed to achieve a precise patient fit using fluoroscopic alignment cues and efficient instrumentation, and provide accuracy to plan.1-8 |
globenewswire.com |
2024-09-10 14:00:00 |
Czytaj oryginał (ang.) |
| Smith & Nephew Delivering On Its Turnaround Promise |
The Street has taken notice of Smith & Nephew's turnaround progress, with better than expected revenue and margin results driving share price outperformance. While the ortho business has continued to grow, SNN has continued to lose share in major joints and this is the biggest item on management's to-do list now. Management has identified additional savings opportunities that will help boost margins further, and coupled with improved sales execution, could drive EBITDA to 30% over the next five years. |
seekingalpha.com |
2024-08-22 00:30:03 |
Czytaj oryginał (ang.) |